Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

JaeSang Ko

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Frontiers in Endocrinology|January 25, 2021
Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital FibroblastsGa Eun Lee, Jinjoo Kim, Jihei Sara Lee, et al.
Plos One|December 22, 2018
Tumor necrosis factor-like weak inducer of apoptosis induces inflammation in Graves' orbital fibroblastsSung Jun Lee, Jinjoo Kim, JaeSang Ko, et al.
ACS Biomaterials Science & Engineering|May 1, 2026
A Clinical Trial Report: A Nasolacrimal Stent with Shape Memory as an Advanced Alternative to Silicone ProductsHyeong Ju Byeon, Jueun Kim, Ju Young Park, et al.
Plos One|August 8, 2020
Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro modelHyeong Ju Byeon, Ji-Young Kim, JaeSang Ko, et al.
Immunopharmacology and Immunotoxicology|November 4, 2024
Therapeutic role of physalin A in the pathogenesis of Graves' orbitopathyEunjin Kim, Ji-Young Kim, Soo Hyun Choi, et al.
Korean Journal of Ophthalmology : KJO|November 8, 2021
Serum Selenium Levels in Patients with Graves Disease: Associations with Clinical Activity and Severity in a Retrospective Case-control StudyTae Hwan Kim, JaeSang Ko, Bo Ram Kim, et al.
Molecular and Cellular Endocrinology|June 11, 2021
Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves' orbitopathyJaeSang Ko, Ji-Young Kim, Bo Ram Kim, et al.
Plos One|December 15, 2022
Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathyHyun Young Park, Min Kyung Chae, JaeSang Ko, et al.
Journal of Molecular Endocrinology|September 16, 2024
Pentraxin 3 mediates inflammation and adipogenesis in Graves' orbitopathy pathogenesisMin Seok Kim, Hyun Young Park, Soo Hyun Choi, et al.
Scientific Reports|September 26, 2025
Nucleus YAP expression as a prognostic biomarker for local recurrence in eyelid sebaceous carcinomaHyeong Ju Byeon, Hyunwook Kim, Myung Soo Chang, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Frontiers in Endocrinology|January 25, 2021
Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital FibroblastsGa Eun Lee, Jinjoo Kim, Jihei Sara Lee, et al.
Plos One|December 22, 2018
Tumor necrosis factor-like weak inducer of apoptosis induces inflammation in Graves' orbital fibroblastsSung Jun Lee, Jinjoo Kim, JaeSang Ko, et al.
ACS Biomaterials Science & Engineering|May 1, 2026
A Clinical Trial Report: A Nasolacrimal Stent with Shape Memory as an Advanced Alternative to Silicone ProductsHyeong Ju Byeon, Jueun Kim, Ju Young Park, et al.
Plos One|August 8, 2020
Protein tyrosine phosphatase 1B as a therapeutic target for Graves' orbitopathy in an in vitro modelHyeong Ju Byeon, Ji-Young Kim, JaeSang Ko, et al.
Immunopharmacology and Immunotoxicology|November 4, 2024
Therapeutic role of physalin A in the pathogenesis of Graves' orbitopathyEunjin Kim, Ji-Young Kim, Soo Hyun Choi, et al.
Korean Journal of Ophthalmology : KJO|November 8, 2021
Serum Selenium Levels in Patients with Graves Disease: Associations with Clinical Activity and Severity in a Retrospective Case-control StudyTae Hwan Kim, JaeSang Ko, Bo Ram Kim, et al.
Molecular and Cellular Endocrinology|June 11, 2021
Signal transducer and activator of transcription 3 as a potential therapeutic target for Graves' orbitopathyJaeSang Ko, Ji-Young Kim, Bo Ram Kim, et al.
Plos One|December 15, 2022
Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathyHyun Young Park, Min Kyung Chae, JaeSang Ko, et al.
Journal of Molecular Endocrinology|September 16, 2024
Pentraxin 3 mediates inflammation and adipogenesis in Graves' orbitopathy pathogenesisMin Seok Kim, Hyun Young Park, Soo Hyun Choi, et al.
Scientific Reports|September 26, 2025
Nucleus YAP expression as a prognostic biomarker for local recurrence in eyelid sebaceous carcinomaHyeong Ju Byeon, Hyunwook Kim, Myung Soo Chang, et al.
Pageof 6